Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
17.00
-0.43 (-2.47%)
At close: Aug 21, 2026, 4:00 PM EDT
16.75
-0.25 (-1.47%)
After-hours: Aug 21, 2026, 7:42 PM EDT
Mesoblast Revenue
Mesoblast had revenue of $51.34M in the half year ending December 31, 2025, with 1,415.41% growth. This brings the company's revenue in the last twelve months to $65.38M, up 1,053.16% year-over-year. In the fiscal year ending June 30, 2025, Mesoblast had annual revenue of $17.20M with 191.39% growth.
Revenue (ttm)
$65.38M
Revenue Growth
+1,053.16%
P/S Ratio
33.63
Revenue / Employee
$807,210
Employees
81
Market Cap
2.20B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 17.20M | 11.30M | 191.39% |
| Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
| Jun 30, 2019 | 16.72M | -619.00K | -3.57% |
| Jun 30, 2018 | 17.34M | 14.93M | 618.95% |
| Jun 30, 2017 | 2.41M | -40.14M | -94.33% |
| Jun 30, 2016 | 42.55M | 9.79M | 29.88% |
| Jun 30, 2015 | 32.76M | 9.37M | 40.05% |
| Jun 30, 2014 | 23.39M | -8.33M | -26.26% |
| Jun 30, 2013 | 31.72M | -7.41M | -18.93% |
| Jun 30, 2012 | 39.12M | -90.48M | -69.81% |
| Jun 30, 2011 | 129.60M | 128.97M | 20,433.19% |
| Jun 30, 2010 | 631.18K | -89.51K | -12.42% |
| Jun 30, 2009 | 720.69K | -152.06K | -17.42% |
| Jun 30, 2008 | 872.75K | -553.16K | -38.79% |
| Jun 30, 2007 | 1.43M | -669.68K | -31.96% |
| Jun 30, 2006 | 2.10M | 1.71M | 447.74% |
| Jun 30, 2005 | 382.59K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 959.90M |
| Aurinia Pharmaceuticals | 311.51M |
| UroGen Pharma | 188.73M |
| Nuvation Bio | 169.90M |
| Ocular Therapeutix | 52.06M |
| Nanobiotix | 38.27M |
MESO News
- 6 days ago - Mesoblast Shares Jump 8.82% on ASX as Biotech Rebounds From Friday's Sharp Selloff Tied to State Street Filing - International Business Times (Australia)
- 6 days ago - Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial - TheFly
- 6 days ago - Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain - GlobeNewsWire
- 24 days ago - Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch - GlobeNewsWire
- 5 weeks ago - Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain - GlobeNewsWire
- 5 weeks ago - Mesoblast reported Q4 Ryoncil net revenue of $36M - TheFly
- 5 weeks ago - Mesoblast rises 6.2% - TheFly
- 6 weeks ago - Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 - GlobeNewsWire